- Home
- LDWY vs BCDA Comparison
LDWY vs BCDA Comparison
Compare LDWY & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- BCDA
- Stock Information
- Founded
- LDWY 1990
- BCDA N/A
- Country
- LDWY United States
- BCDA United States
- Employees
- LDWY N/A
- BCDA N/A
- Industry
- LDWY Advertising
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- BCDA Health Care
- Exchange
- LDWY Nasdaq
- BCDA Nasdaq
- Market Cap
- LDWY 6.7M
- BCDA 7.9M
- IPO Year
- LDWY 1991
- BCDA N/A
- Fundamental
- Price
- LDWY $3.42
- BCDA $2.60
- Analyst Decision
- LDWY
- BCDA Strong Buy
- Analyst Count
- LDWY 0
- BCDA 1
- Target Price
- LDWY N/A
- BCDA $25.00
- AVG Volume (30 Days)
- LDWY 9.9K
- BCDA 74.1K
- Earning Date
- LDWY 11-11-2024
- BCDA 11-06-2024
- Dividend Yield
- LDWY N/A
- BCDA N/A
- EPS Growth
- LDWY N/A
- BCDA N/A
- EPS
- LDWY N/A
- BCDA N/A
- Revenue
- LDWY $24,813,000.00
- BCDA $428,000.00
- Revenue This Year
- LDWY N/A
- BCDA $6.92
- Revenue Next Year
- LDWY N/A
- BCDA N/A
- P/E Ratio
- LDWY N/A
- BCDA N/A
- Revenue Growth
- LDWY N/A
- BCDA 0.71
- 52 Week Low
- LDWY $3.02
- BCDA $1.96
- 52 Week High
- LDWY $6.88
- BCDA $23.25
- Technical
- Relative Strength Index (RSI)
- LDWY 46.04
- BCDA 46.60
- Support Level
- LDWY $3.34
- BCDA $2.39
- Resistance Level
- LDWY $3.66
- BCDA $2.84
- Average True Range (ATR)
- LDWY 0.20
- BCDA 0.17
- MACD
- LDWY 0.04
- BCDA -0.00
- Stochastic Oscillator
- LDWY 62.50
- BCDA 41.18
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two Industry Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).